Patients with cardiac gene mutations have increased rates of neurological disorders: high rates of epilepsy in patients with LQT2 syndrome due to KCNH2 mutations (66) and high rates of neurodevelopmental delay in patients with CPVT due to RYR2 mutations (67). This evidence concerns the gene KCNH2 and epilepsy.